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Abstract
Transcranial direct current stimulation (tDCS) is a non-invasive brain stim-
ulation method that is frequently used to study cortical excitability changes
and their impact on cognitive functions in humans. While most stimulators
are capable of operating in double-blind mode, the amount of discomfort ex-
perienced during tDCS may break blinding. Therefore, specifically designed
sham stimulation protocols are being used. The “fade-in, short-stimulation,
fade-out” (FSF) protocol has been used in hundreds of studies and is com-
monly believed to be indistinguishable from real stimulation applied at 1 mA
for 20 minutes. We analyzed subjective reports of 192 volunteers, who either
received real tDCS (n=96) or FSF tDCS (n=96). Participants reported more
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discomfort for real tDCS and correctly guessed the condition above chance-
level. These findings indicate that FSF does not ensure complete blinding
and that better active sham protocols are needed.
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1. Introduction1
Transcranial direct current stimulation (tDCS) is a safe, non-invasive2
brain stimulation method, which applies low-intensity (most frequently 1-23
mA) constant current between two or more electrodes placed over the scalp4
(Antal et al., 2017). tDCS is assumed to modulate cortical excitability de-5
pending on the polarity of the stimulation and is used to study cognitive6
functions in humans (Santarnecchi et al., 2015). At low intensities, tDCS7
induces a moderate amount of perceptual adverse effects that include cu-8
taneous discomfort such as itching, tingling, burning or piercing sensations9
(Poreisz et al., 2007; Matsumoto and Ugawa, 2017; Fertonani et al., 2015).10
Most tDCS studies use active sham stimulation protocols for placebo con-11
trol (Davis et al., 2013). The aim of active sham stimulation is to induce12
cutaneous adverse effects that are indistinguishable from the real tDCS pro-13
tocol without inducing the neurophysiologically relevant primary effects of14
the stimulation (Woods et al., 2016). The most frequently applied active15
sham stimulation is the so called ‘fade-in, short-stimulation, fade-out’ (FSF)16
protocol (Ambrus et al., 2012). The FSF protocol consists of three stimu-17
lation stages: It starts with a fade-in period, where the current is gradually18
ramped up from 0 mA to the planned intensity (e.g., 1 mA) in a relatively19
short (5-30s) time period. The second stage is the short stimulation period20
at the planned intensity, which lasts for only a very brief time period (most21
commonly for 30s). The final stage is the fade-out period, in which the cur-22
rent is gradually ramped down from the planned stimulation intensity to 023
mA over a short (5-30s) time period. The FSF protocol is an extension of24
the initial “FS protocol”, which only consists of the initial fade-in and the25
short-stimulation periods (Gandiga et al., 2006). It is commonly believed26
that the fade-out period at the end of the active sham stimulation protocol27
further improves its blinding efficacy and therefore, the FS protocol is rarely28
applied.29
The blinding efficacy of the FSF protocol depends on the intensity and30
duration of the real tDCS protocol to which it is being compared. While it is31
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commonly assumed that FSF can maintain blinding at 1 mA applied for 2032
minutes (based on findings from the FS protocol from Gandiga et al., 2006),33
evidence suggests that blinding is compromised when tDCS is applied at 1.534
or 2 mA for 10 minutes or longer (Kessler et al., 2012; O’Connell et al., 2012;35
Russo et al., 2013; Wallace et al., 2016). Following these findings, FSF has36
been used as a control in hundreds of studies using real tDCS at 1 mA for37
20 minutes.38
Given the enormous popularity of this sham procedure (Bikson et al.,39
2017), we set out to investigate its blinding efficacy using data from our recent40
high-powered, multi-center, pre-registered study (Boayue et al., in press). In41
this study, we collected data from 192 volunteers, who either received real42
tDCS at 1 mA for 20 minutes over the left dorsolateral prefrontal cortex43
(DLPFC) or FSF tDCS. The primary goal was to investigate the behavioral44
effects of anodal tDCS over the left DLPFC on mind-wandering but we also45
collected subjective reports concerning blinding efficacy and cutaneous dis-46
comfort. Here, we analyze these subjective reports in order to investigate47
whether FSF is an effective control procedure for tDCS applied at 1 mA over48
20 minutes.49
2. Material and methods50
The study followed a fully pre-registered protocol (https://osf.io/51
bv32d/) with a sequential sampling plan for the primary research question52
(Boayue et al., in press). However, none of the analyses reported in the53
current paper were pre-registered.54
2.1. Participants55
The dataset contains subjective reports of 192 healthy participants (13456
female, mean age: 22.2 yrs ± 3.19 yrs SD). Data was collected at three57
labs (N per lab=64): Amsterdam, Goettingen and Tromsø (Boayue et al., in58
press). The raw data and all analyses reported here are available for down-59
load at our repository (https://github.com/ihrke/2018_tdcs_blinding).60
Participants had no contraindication and no previous experience with tDCS61
as was assessed by self-reports. The study was approved by the local ethic62
committee and was performed according to the Declaration of Helsinki. All63
participants provided written informed consent before participation.64
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2.2. Experimenter65
The experimenters were responsible for the recruitment and data collec-66
tion in each center (Amsterdam, Göttingen, Tromsø). As part of the training,67
all experimenters were instructed about safety, ethical considerations of tran-68
scranial electrical stimulation and about the principles of good scientific prac-69
tice. Before the start of the pilot measurement, the experimenters received a70
series of written, video and in-person training about the correct application of71
tDCS. The training ensured that the quality of electrode preparation was ap-72
propriate, including finding the target location, cleaning the skin, preparing73
the skin-electrode interface and applying the conductive medium. The exper-74
imenters followed a fully pre-registered protocol, standardized across labs. In75
each lab, the experimenters collected at least two pilot measurements before76
the data collection of the real experiment. Data from the pilot measurements77
were not included in the data analysis. During the pilot experiments, the78
experimenters were supervised by a researcher with history of prior experi-79
ence in tDCS. The real data collection started when the experimenter met80
the requirement of performing tDCS independently.81
The experimenter in Amsterdam was a native Dutch speaker (author82
J.G.), whereas the experimenter in Goettingen was a native German, male83
medical student (6-7th semester). Three experimenters collected the data in84
Tromsø, (including author N.M.B.). Two were native Norwegian speakers85
(one female, one male), whereas N.M.B. is fluent Norwegian speaker at C186
level (according to the Common European Framework of Reference for Lan-87
guages). Instructions were fully computerized and translated into the local88
languages by competent, native speakers.89
2.3. Electrode preparation and stimulation protocols90
The fully pre-registered protocol detailing electrode preparation and stim-91
ulation application steps is available at the following location (https://osf.92
io/qdk3x/) and summarized below.93
First, the electrode locations were determined using an EEG cap adjusted94
for head size. Then, alcohol on de-makeup pads was used to clean the skin95
surface where electrodes were positioned. A small amount of Ten20 con-96
ductive electrode paste (Weaver and Company, USA) was homogeneously97
distributed over the previously cleaned skin areas and on the surfaces of the98
rubber electrodes. Medium pressure was applied to enable good electrode-99
skin contact. The anode electrode (4×4 cm) was placed over the F3 location100
(according to the international 10/20 EEG system), whereas the cathode101
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(7 × 5 cm) over the right supraorbital region. The electrodes were held in102
place by the conductive electrode paste and two loops of cohesive elastic103
fixation bandage (MaiMed GmbH, Germany). The pressure of the elastice104
bandage was adjusted individually to avoid too much pressure on the head105
while maintaining proper fixation. Impedance levels were required to be ≤106
10kΩ.107
The stimulation was administered using a neuroConn DC-stimulator (neu-108
roConn GmbH, Germany). The real tDCS protocol lasted for 20 minutes of109
continuous stimulation at 1 mA, whereas the FSF protocol for 15s at 1 mA.110
In addition, we utilized 30s-long fade-in/out periods at the beginning and111
at the end of both tDCS protocols. The details of the real and the FSF112
protocols are summarized in Figure 1 A and B. The stimulator was operat-113
ing in study mode: The active sham and the real stimulation protocols were114
assigned to pseudo-codes B and C, respectively.115
The data was collected in a double-blind fashion. Although neuroConn116
DC-stimulators can run in double-blind stimulation mode, the built-in ac-117
tive sham protocol consists of 30s fade-in/out periods and a 40s-long short-118
stimulation period. However, due to the nature of the present pre-registered119
replication study (Boayue et al., in press), the active sham protocol was con-120
fined to 15s which is why double-blind mode could not be used. Since the121
display window of the stimulator between protocols was slightly different, it122
was covered 30s after the start (until that time the displays were identical)123
of the stimulation to avoid accidental unblinding of the experimenter.124
Participants performed a cognitive task (Sustained Attention to Response125
Task; SART) while receiving the stimulation (Boayue et al., in press). The126
total duration of the SART was 40 minutes, and tDCS was applied in the127
first 20 minutes. In the informed consent, participants were informed about128
the intensity and the duration of the real stimulation condition. Participants129
were also informed that they would either receive real or placebo stimulation.130
The details of the placebo stimulation (i.e., duration and intensity) were not131
specified, only that it would feel identical to the real stimulation condition132
but would purportedly apply no current.133
2.4. Assessing stimulation discomfort and blinding efficacy134
A 7-point Likert-scale was used to assess the amount of discomfort and135
the blinding efficacy of the FSF protocol. The questionnaires were completed136
at the end of the experiment by the participants. To investigate the amount137
of discomfort, participants were required to answer the question “Please rate138
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the magnitude to which the placement and/or effect of either electrode was139
disturbing during the task (e.g., feeling that the electrodes were dislocated,140
wet or cold feeling in the skin under the electrodes, tingling or itching in141
the skin under the electrodes, etc.)!”. Available response categories ranged142
from “not at all” (1) to “very strong” (7). To study the blinding efficacy,143
participants were asked to answer the question “Please tell us if you think144
you were receiving real or fake (placebo) stimulation today!” with response145
categories between “definitely sham” (1) and “definitely real” (7).146
2.5. Analysis method147
We used Bayesian estimation of ordinal probit regression models (Bürkner148
and Vuorre, 2018) designed specifically for analysing ordinal data (Liddell149
and Kruschke, 2018). We report our results in terms of posterior mean pa-150
rameters along with the 95% highest-density interval (HDI) calculated from151
the posterior distribution. This measure quantifies the interval in which the152
true parameter is located with 95% probability given the applied model. We153
conclude that a parameter is different from zero if the 95% interval excludes154
zero. For more details, see Supplemental Analyses.155
3. Results156
Our results are summarized graphically in Figure 1 C and 1 D. Regarding157
the blinding efficacy, excluding subjects who were undecided, there were 2.6158
as many subjects in the real stimulation group who guessed that they received159
real stimulation (52 with scores > 4 vs. 20 with scores < 4). In contrast, this160
figure was only 1.19 for the sham group (38 with scores > 4 vs. 32 with scores161
< 4). We submitted these responses for guessing stimulation condition to162
an ordinal regression model using lab (Amsterdam, Goettingen, Tromsø) and163
actual stimulation condition (anodal, sham) as predictors. We found that the164
effect of real stimulation was reliable (b = 0.35, HDI=[0.06, 0.65]). This effect165
was robust against different choices of the analysis method (see Supplemental166
Analysis). While including lab as a factor was preferred by model-selection167
criteria, there was no clear effect for generally higher or lower scores across168
labs (bGOE = 0.33 [−0.03, 0.69], bTRM = −0.10 [−0.45, 0.28]).169
The findings for the discomfort question were similar. In general, all170
subjects reported relatively low discomfort (M = 2.5, SD=1.56). In a par-171
allel model to that for the blinding question, real stimulation had a positive172
effect (b = 0.34 [0.04, 0.63]) though that effect was slightly less robust to173
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Figure 1: (A) The stimulation parameters for the real and FSF tDCS protocols. (B) The
electrode montage. (C) Responses to the blinding question were generally more correct
in the real-stimulation condition (red) when compared to sham (grey). (D) Participants
receiving real stimulation reported greater discomfort.
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model-specification than the effect on the blinding question (see Supplemen-174
tal Analyses).175
4. Discussion176
TDCS applied at 1 mA for 20 minutes is one of the most frequently177
used protocols in the literature and it is commonly assumed to be effectively178
blinded by the FSF protocol (Gandiga et al., 2006). Our data, collected from179
a brain stimulation study with the highest sample size investigating this issue180
to date, challenge this assumption: We found that our subjects could, to a181
degree, distinguish between active and sham conditions. It is important to182
note that this effect was present despite the fact that 1) none of the partici-183
pants had any prior experience with tDCS and 2) every participant took part184
in only one condition so that they did not have a reference frame to which185
to compare their experience. It is likely that the actual distinguishability186
can be much stronger in many studies using repeated measures (O’Connell187
et al., 2012; Greinacher et al., 2018) and/or participants with prior exposure188
to tDCS (Ambrus et al., 2012). This effect may be even more pronounced in189
the clinical context: Whereas healthy participants most frequenty subject to190
single-session tDCS, patients usually receive multi-session tDCS over a dura-191
tion of several weeks (Loo et al., 2018). Furthermore, we found compromised192
blinding despite the fact the our participants received no detailed informa-193
tion about the active sham protocol (O’Connell et al., 2012). We expect194
that informing the participants about the details of the active sham protocol195
in the informed consent forms (which may be recquired in certain clinical196
context or requested by the local ethic committees) can further facilite the197
correct identification of the different stimulation conditions.198
The assumption that 1 mA tDCS for 20 minutes can be effectively blinded199
by the FSF protocol is based on a single study including 24 healthy volunteers200
and 23 chronic stroke patients with a mean age between 46.3 and 62.3 years201
(Gandiga et al., 2006). Recent evidence indicates that the tDCS-induced202
discomfort may depend on age: It is lower in older than in younger partici-203
pants (Wallace et al., 2016). This difference in the sensitivity may be part of204
the reason why our younger volunteers (mean age: 22.2 years) could better205
distinguish between real and active sham stimulation protocols than older206
participants (Gandiga et al., 2006), and also explain why the blinding was207
compromised among younger adults. Given that a large number of tDCS208
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studies recruits young adults, our finding is an important contribution to the209
field.210
In a recent pre-registered study it was shown that the blinding efficacy211
of the FSF protocol is compromised even for the most frequenty used 1 mA212
and 10 minute-long real tDCS protocol, when a repeated-measure study de-213
sign is used (Greinacher et al., 2018). In this study, tDCS was applied over214
the left primary motor cortex (anode) and over the right supraorbital re-215
gion (cathode). The FSF protocol consisted of 30s fade-in/out periods and216
20s short stimulation period (Greinacher et al., 2018). FSF protocols in217
this stimulation parameter range were previously assumed to be effective for218
maintaining blinding (Ambrus et al., 2012). Contrary to the expectations,219
participants were able to correctly idenfity active sham and real tDCS proto-220
cols based on the differences in the time course of the subjectively perceived221
cutaneous discomfort (Greinacher et al., 2018). The stimulation parame-222
ters used in this study were similar to the ones reported here: Both used 1223
mA tDCS, comparable electrode montage and a FSF protocol (with identi-224
cal fade-in/out periods and similar short stimulation periods: 15s vs 20s).225
One important difference is the duration of the real tDCS: Whereas in our226
study it was 20 minutes, Greinacher et al. (2018) used 10 minutes. Blinding227
efficacy of FSF protocols seems to be better for real tDCS protocols with228
shorther stimulation durations (e.g., 10 minutes). This may explain why229
our participants (receiving 20 minutes tDCS) were able to correctly iden-230
tify stimulation conditions, even after a single stimulation session. Another231
important difference between the two studies is the way blinding efficacy232
was assessed. In Greinacher et al. (2018), participants were asked every 30s233
whether they think the stimulation is on (yes or no) and how confident they234
are in their answers (11-point Likert-scale). Altough this study provided de-235
tailed information about the actual time-course of the subjectively perceived236
cutaneous-sensations associated with different tDCS protocols, one may ar-237
gue that this procedure inevitably biased the participants toward focusing238
more on skin-sensations. In our study, participants performed a cognitive239
task while receiving the stimulation and they were only asked about blinding240
retrospectively. The assessment method used by our study is the most com-241
mon way in studies aiming to measure the possible cognitive effects of tDCS242
and the blinding efficacy of the sham/control stimulation relative to the real243
tDCS protocol.244
In the present study, we used Ten20 conductive paste instead of saline245
solution or conductive gel. The use of gel and conductive paste has become246
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increasingly popular over recent years (Saturnino et al., 2015; Woods et al.,247
2016). Application of conductive paste has several advantages over saline248
solution that includes better control of the spread of the conductive medium249
over the skin and better adherence to the curved surface of the skull. This250
allows more stable positioning compared to the saline-saturated sponge and251
rubber bandage method. Moreover, it can be safely combined with func-252
tional magnetic resonance imaging and there is no need for rehydration over253
the time-course of longer stimulation sessions. We do not believe that the254
choice of conductive medium has an impact on blinding efficacy for the fol-255
lowing reasons. While there is some evidence that cutaneous sensations even256
in the most commonly used saline solution at various concentration levels257
(15, 140 and 220 mM) may be perceived differently by participants (Dundas258
et al., 2007), the low sample size (N=14) does not permit to draw strong259
conclusions. We are unaware of any studies explicitly assessing the level260
of discomfort and the efficacy of blinding using different conductive media.261
However, a computational modeling study compared peak electric fields in262
the skin of the most commonly used conductive media, including “Spectra263
360” gel, “Signa Gel” and “Ten20” (Saturnino et al., 2015). This study264
found highest peak electric field in the skin for the lower gel conductivities265
but it is unclear how these differences in peak electric field magnitudes are266
translated into subjectively-experienced cutaneous discomfort. Furthermore,267
other studies that have demonstrated ineffective blinding for FSF employed268
saline solution (O’Connell et al., 2012; Greinacher et al., 2018).269
Given the accumulating evidence about ineffective blinding of the FSF270
protocol for real tDCS between 1 and 2 mA over 10 and 30 minutes (O’Connell271
et al., 2012; Kessler et al., 2012; Russo et al., 2013; Wallace et al., 2016;272
Greinacher et al., 2018), we conclude that our findings are not limited to the273
exact stimulation parameters used in this study, but instead demonstrate a274
general pattern about ineffective blinding for the most commonly used stim-275
ulation protocols. Given that tDCS is a potent placebo-inducing procedure276
both in the clinical (Aslaksen et al., 2014) and cognitive domains (Turi et al.,277
2017, in press), there seems to be an urgent need to test alternative active278
sham protocols (Palm et al., 2013; Boonstra et al., 2016) or develop better279
active sham protocols to effectively maintain blinding. One possibility may280
be to consider to utilize topical anaesthetic cream to reduce cutaneous sensa-281
tions (McFadden et al., 2011; Guleyupoglu et al., 2014; Guarienti et al., 2015)282
and vasodilatation-induced redness underneath the electrodes (Durand et al.,283
2002; O’Connell et al., 2012; Ezquerro et al., 2017) both of which have previ-284
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ously been identified as potential factors which can break blinding (O’Connell285
et al., 2012; Palm et al., 2013; Guarienti et al., 2015).286
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